Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SVRA Stock 12 Month Forecast
Average Price Target
$10.25
▲(79.82% Upside)
| Highest Price Target$11.00 | Average Price Target$10.25 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$11
Buy
92.98%
Upside
Reiterated
02/23/26
We are pleased to see the MOLBREEVI BLA filed, following its resubmission. Addionally , we are encouraged to see Priority Review granted (no real surprise), with PDUFA date set for 8/22/26. As we connue to believe the data package robustly demonstrates MOLBREEVI's efficacy and safety for the treatment of autoimmune PAP (aPAP), we expect approval. As a reminder, MOLBREEVI has already been granted FTD, BTD, ODD (FDA/EMA), and Innovaon Passport (IP) and Promising Innovave Medicine (PIM) by UK's MHRA. SVRA plans to submit MOLBREEVI Markeng Authorizaon Applicaon (MAAs) for aPAP to the EMA and MHRA by end of 1Q26. Based on the strength of the data, and our recent KOL checks - which emphasized the potenal usage of MOLBREEVI across all paents (mild, moderate and severe) - we believe MOLBREEVI is well-posioned for commercial success.
H.C. Wainwright
$8→$10
Buy
75.44%
Upside
Reiterated
12/23/25
Wells Fargo
$7→$9
Buy
57.89%
Upside
Reiterated
12/17/25
Oppenheimer
$8→$9
Buy
57.89%
Upside
Reiterated
11/14/25
Citizens JMP
$8→$11
Buy
92.98%
Upside
Reiterated
10/23/25
Piper Sandler
$16
Buy
180.70%
Upside
Reiterated
09/03/25
Evercore ISI
$2
Hold
-64.91%
Downside
Reiterated
08/04/25
Jefferies
$8.5
Buy
49.12%
Upside
Reiterated
03/26/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$11
Buy
92.98%
Upside
Reiterated
02/23/26
We are pleased to see the MOLBREEVI BLA filed, following its resubmission. Addionally , we are encouraged to see Priority Review granted (no real surprise), with PDUFA date set for 8/22/26. As we connue to believe the data package robustly demonstrates MOLBREEVI's efficacy and safety for the treatment of autoimmune PAP (aPAP), we expect approval. As a reminder, MOLBREEVI has already been granted FTD, BTD, ODD (FDA/EMA), and Innovaon Passport (IP) and Promising Innovave Medicine (PIM) by UK's MHRA. SVRA plans to submit MOLBREEVI Markeng Authorizaon Applicaon (MAAs) for aPAP to the EMA and MHRA by end of 1Q26. Based on the strength of the data, and our recent KOL checks - which emphasized the potenal usage of MOLBREEVI across all paents (mild, moderate and severe) - we believe MOLBREEVI is well-posioned for commercial success.
H.C. Wainwright
$8→$10
Buy
75.44%
Upside
Reiterated
12/23/25
Wells Fargo
$7→$9
Buy
57.89%
Upside
Reiterated
12/17/25
Oppenheimer
$8→$9
Buy
57.89%
Upside
Reiterated
11/14/25
Citizens JMP
$8→$11
Buy
92.98%
Upside
Reiterated
10/23/25
Piper Sandler
$16
Buy
180.70%
Upside
Reiterated
09/03/25
Evercore ISI
$2
Hold
-64.91%
Downside
Reiterated
08/04/25
Jefferies
$8.5
Buy
49.12%
Upside
Reiterated
03/26/25
Best Analysts Covering Savara
3 Months
xxx
Success Rate
6/11 ratings generated profit
Average Return
+8.39%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +8.39% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+19.65%
reiterated a buy rating 6 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +19.65% per trade.
2 Years
xxx
Success Rate
14/15 ratings generated profit
Average Return
+41.98%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +41.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SVRA Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
11
12
11
9
6
Buy
0
0
1
1
1
Hold
1
0
1
7
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
12
13
17
14
Each month's total comprises the sum of three months' worth of ratings.
SVRA Financial Forecast
SVRA Stock Forecast FAQ
What is SVRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Savara’s 12-month average price target is 10.25.
What is SVRA’s upside potential, based on the analysts’ average price target?
Savara has 79.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SVRA a Buy, Sell or Hold?
Savara has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Savara’s price target?
The average price target for Savara is 10.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $9.00. The average price target represents 79.82% Increase from the current price of $5.7.
The highest analyst price target is $11.00 ,the lowest forecast is $9.00. The average price target represents 79.82% Increase from the current price of $5.7.
What do analysts say about Savara?
Savara’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of SVRA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.